Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives. We’ve already achieved significant milestones on our path to gaining FDA approval for the first lifespan extension drug for any species. We have three products in our pipeline and expect to bring the first product to market in 2025. Our team includes scientists, veterinarians, engineers, operators, and creatives. Join us in our mission to help dogs everywhere.
$22M sweet spot round size
2020
$22M
from 2 investors over 1 rounds
Loyal raised $22M on March 26, 2025
Investors: Valor Equity Partners and Collaborative Fund